Roche’s $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

Swiss drugmaker Roche’s $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.

…read more

Source:: Reuters – Business News